Roth R A, Maddux B, Wong K Y, Styne D M, Van Vliet G, Humbel R E, Goldfine I D
Endocrinology. 1983 May;112(5):1865-7. doi: 10.1210/endo-112-5-1865.
A monoclonal antibody to the human insulin receptor was tested for its ability to inhibit the binding of 125I-insulin-like growth factor I (IGF-I) and 125I-insulin-like growth factor II (IGF-II) to their receptors in human placenta membranes and cultured human IM-9 lymphocytes. In both placenta membranes and IM-9 cells, the antibody progressively inhibited the binding of 125I-IGF-I to its receptor with a potency that was 300-fold less than its ability to inhibit the binding of 125I-insulin to its own receptor. In contrast, in human placenta membranes, this antibody inhibited the binding of 125I-IGF-II to its receptor only slightly. These studies indicate, therefore, that this monoclonal antibody binds preferentially to the insulin receptor but also crossreacts to a lesser extent with the IGF-I receptor.
一种针对人胰岛素受体的单克隆抗体,被测试其抑制125I-胰岛素样生长因子I(IGF-I)和125I-胰岛素样生长因子II(IGF-II)与它们在人胎盘膜和培养的人IM-9淋巴细胞中的受体结合的能力。在胎盘膜和IM-9细胞中,该抗体逐渐抑制125I-IGF-I与其受体的结合,其效力比抑制125I-胰岛素与其自身受体结合的能力低300倍。相反,在人胎盘膜中,该抗体仅轻微抑制125I-IGF-II与其受体的结合。因此,这些研究表明,这种单克隆抗体优先结合胰岛素受体,但也与IGF-I受体有较小程度的交叉反应。